Vascular Biogenics Ltd. (NASDAQ:VBLT) has received an average recommendation of “Hold” from the six ratings firms that are covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating and four have assigned a buy rating to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $14.75.

VBLT has been the subject of several recent research reports. Zacks Investment Research upgraded shares of Vascular Biogenics from a “sell” rating to a “hold” rating in a research note on Wednesday, July 19th. ValuEngine upgraded shares of Vascular Biogenics from a “sell” rating to a “hold” rating in a research note on Wednesday, September 20th. Finally, HC Wainwright set a $11.00 target price on shares of Vascular Biogenics and gave the stock a “buy” rating in a research note on Tuesday, August 15th.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another domain, it was stolen and republished in violation of international trademark and copyright laws. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/10/11/vascular-biogenics-ltd-vblt-receives-average-rating-of-hold-from-brokerages.html.

A hedge fund recently raised its stake in Vascular Biogenics stock. Menta Capital LLC lifted its holdings in Vascular Biogenics Ltd. (NASDAQ:VBLT) by 5.4% in the first quarter, according to the company in its most recent filing with the SEC. The fund owned 121,935 shares of the biopharmaceutical company’s stock after acquiring an additional 6,200 shares during the quarter. Menta Capital LLC owned 0.45% of Vascular Biogenics worth $671,000 at the end of the most recent quarter. 11.19% of the stock is currently owned by institutional investors and hedge funds.

Shares of Vascular Biogenics (NASDAQ:VBLT) traded up 3.64% on Wednesday, hitting $6.40. 192,236 shares of the company’s stock were exchanged. The firm has a market cap of $173.54 million, a P/E ratio of 9.70 and a beta of -3.09. Vascular Biogenics has a 12 month low of $3.90 and a 12 month high of $7.25. The stock’s 50 day moving average is $5.64 and its 200 day moving average is $5.20.

Vascular Biogenics (NASDAQ:VBLT) last posted its earnings results on Monday, August 14th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.01. On average, equities analysts predict that Vascular Biogenics will post ($0.74) earnings per share for the current year.

Vascular Biogenics Company Profile

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.

Receive News & Ratings for Vascular Biogenics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.